| Primary |
| Acute Myeloid Leukaemia |
43.1% |
| Acute Lymphocytic Leukaemia |
23.4% |
| B Precursor Type Acute Leukaemia |
3.2% |
| Diffuse Large B-cell Lymphoma |
2.6% |
| Myelodysplastic Syndrome |
2.5% |
| Mantle Cell Lymphoma |
2.4% |
| Product Used For Unknown Indication |
2.3% |
| Non-hodgkin's Lymphoma |
2.3% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
2.0% |
| Prophylaxis |
1.9% |
| Leukaemia |
1.8% |
| Hodgkin's Disease |
1.7% |
| Non-hodgkin's Lymphoma Unspecified Histology Aggressive |
1.7% |
| Acute Leukaemia |
1.5% |
| Burkitt's Lymphoma |
1.4% |
| T-cell Lymphoma |
1.4% |
| Acute Promyelocytic Leukaemia |
1.4% |
| Chronic Lymphocytic Leukaemia |
1.3% |
| T-cell Type Acute Leukaemia |
1.2% |
| Acute Myelomonocytic Leukaemia |
1.1% |
|
| White Blood Cell Count Decreased |
12.1% |
| Febrile Neutropenia |
10.7% |
| Pyrexia |
10.1% |
| Thrombocytopenia |
9.0% |
| Sepsis |
8.5% |
| Vomiting |
8.5% |
| Septic Shock |
6.0% |
| Neutropenia |
4.7% |
| Tachycardia |
3.8% |
| Pneumonia |
3.1% |
| Staphylococcal Infection |
3.1% |
| Respiratory Failure |
3.0% |
| Tumour Lysis Syndrome |
2.7% |
| Unresponsive To Stimuli |
2.6% |
| Pancytopenia |
2.4% |
| Renal Failure Acute |
2.3% |
| Myelodysplastic Syndrome |
2.0% |
| Tachypnoea |
2.0% |
| Stem Cell Transplant |
1.9% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
1.7% |
|
| Secondary |
| Acute Lymphocytic Leukaemia |
22.9% |
| Acute Myeloid Leukaemia |
21.1% |
| Product Used For Unknown Indication |
8.4% |
| Burkitt's Lymphoma |
7.5% |
| Mantle Cell Lymphoma |
5.9% |
| Prophylaxis |
4.7% |
| Non-hodgkin's Lymphoma |
4.1% |
| Drug Use For Unknown Indication |
3.3% |
| Diffuse Large B-cell Lymphoma |
3.0% |
| Lymphoma |
2.6% |
| Burkitt's Leukaemia |
2.3% |
| Myelodysplastic Syndrome |
2.2% |
| B Precursor Type Acute Leukaemia |
1.9% |
| B-cell Lymphoma |
1.8% |
| Acute Promyelocytic Leukaemia |
1.6% |
| Chromosome Analysis Abnormal |
1.4% |
| Central Nervous System Lymphoma |
1.4% |
| Chemotherapy |
1.2% |
| Hodgkin's Disease |
1.2% |
| T-cell Type Acute Leukaemia |
1.2% |
|
| Sepsis |
12.4% |
| Thrombocytopenia |
10.2% |
| Vomiting |
6.5% |
| Febrile Neutropenia |
6.5% |
| Pyrexia |
6.1% |
| White Blood Cell Count Decreased |
6.0% |
| Death |
5.9% |
| Septic Shock |
5.9% |
| Neutropenia |
4.8% |
| Infection |
4.0% |
| Pneumonia |
4.0% |
| Respiratory Failure |
3.6% |
| Off Label Use |
3.5% |
| Venoocclusive Liver Disease |
3.4% |
| Myelodysplastic Syndrome |
3.2% |
| Pancytopenia |
3.2% |
| Stomatitis |
3.0% |
| Multi-organ Failure |
2.9% |
| Renal Failure |
2.6% |
| Acute Myeloid Leukaemia |
2.3% |
|
| Concomitant |
| Acute Lymphocytic Leukaemia |
14.6% |
| Product Used For Unknown Indication |
11.4% |
| Prophylaxis |
10.6% |
| Acute Myeloid Leukaemia |
9.3% |
| Drug Use For Unknown Indication |
8.0% |
| Prophylaxis Against Graft Versus Host Disease |
6.4% |
| Infection Prophylaxis |
6.2% |
| Bone Marrow Conditioning Regimen |
6.1% |
| Diffuse Large B-cell Lymphoma |
3.5% |
| Neoplasm Malignant |
2.8% |
| Stem Cell Transplant |
2.8% |
| Non-hodgkin's Lymphoma |
2.8% |
| Lymphoma |
2.5% |
| Premedication |
2.2% |
| Antifungal Prophylaxis |
2.1% |
| Febrile Neutropenia |
2.1% |
| Chemotherapy |
2.0% |
| B-cell Lymphoma |
1.9% |
| Burkitt's Lymphoma |
1.5% |
| Pyrexia |
1.2% |
|
| White Blood Cell Count Decreased |
11.7% |
| Vomiting |
9.4% |
| Sepsis |
8.8% |
| Acute Myeloid Leukaemia |
6.9% |
| Thrombocytopenia |
6.9% |
| Pyrexia |
6.8% |
| Drug Ineffective |
5.8% |
| Septic Shock |
5.1% |
| Respiratory Failure |
4.0% |
| Weight Increased |
4.0% |
| Febrile Neutropenia |
3.9% |
| Venoocclusive Liver Disease |
3.5% |
| Stomatitis |
3.4% |
| Multi-organ Failure |
3.1% |
| Mucosal Inflammation |
2.9% |
| Renal Failure Acute |
2.9% |
| Acute Graft Versus Host Disease |
2.8% |
| Neutropenia |
2.8% |
| Pancytopenia |
2.7% |
| Renal Failure |
2.7% |
|
| Interacting |
| Non-hodgkin's Lymphoma Unspecified Histology Aggressive |
33.6% |
| Non-hodgkin's Lymphoma |
25.2% |
| Product Used For Unknown Indication |
14.0% |
| Hepatosplenic Candidiasis |
10.3% |
| Chronic Lymphocytic Leukaemia |
4.7% |
| Diffuse Large B-cell Lymphoma |
3.7% |
| Leukaemia |
2.8% |
| Myeloid Leukaemia |
1.9% |
| Thrombosis Prophylaxis |
1.9% |
| Acute Promyelocytic Leukaemia |
0.9% |
| Nausea |
0.9% |
|
| Drug Interaction |
14.3% |
| Pyrexia |
10.7% |
| Sinoatrial Block |
10.7% |
| Agranulocytosis |
7.1% |
| Apnoea |
7.1% |
| Arrhythmia |
7.1% |
| Atrioventricular Block Second Degree |
7.1% |
| International Normalised Ratio Increased |
7.1% |
| Leukopenia |
7.1% |
| Neutropenia |
7.1% |
| Neoplasm Progression |
3.6% |
| Pancytopenia |
3.6% |
| Sinus Bradycardia |
3.6% |
| Sinus Tachycardia |
3.6% |
|
